Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events

Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM. Enhancement of nitric oxide ( NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (T-max = 1h; T-1/2 = 1.2 h), although erectile effects have been observed after 7 h. In humans, vardenafil is rapidly absorbed (T-max approximate to 40 min) and more slowly metabolized (T-1/2 approximate to 4 h), with an absolute bioavailability of 14.5% ( vs 40% for sildenafil). Although the consumption of high-fat meals does not affect the drug's relative bioavailability, it retards intestinal absorption. Coadministration of CYP3A4 inhibitors such as ritonavir can affect hepatic metabolism. M1, an active metabolite of vardenafil, is a four-fold-less potent inhibitor of PDE5 than its parent compound, contributing approximately 7% to vardenafil's overall efficacy. The side effects of all selective PDE5 inhibitors commonly include vasodilation, small reductions in blood pressure, headache, and nasal congestion.